Highlights

  • DAYBUE (trofinetide) net sales reached US$101 million in Q1 2026, up 20% on Q1 2025 — the highest year-on-year growth rate since Q3 2024 — with full-year FY26 sales guidance reaffirmed by Acadia at US$460–490 million.
  • Neuren earned Q1 2026 Royalty income of US$10.4 million, up 23% on Q1 2025, with full-year royalty guidance maintained at US$50–54 million (approximately A$70–77 million at assumed AUD/USD rates of 0.70–0.72).
  • NEU shares rose 4.38% to $12.86 on 7 May 2026; DAYBUE STIX — the new powder formulation — received an encouraging limited launch with more than 250 prescriptions and caregiver satisfaction exceeding 80%.

 

Neuren Pharmaceuticals Limited (ASX:NEU), the Melbourne-based rare neurological disorder-focused biotech, reported a strong start to FY26 on 7 May 2026, with its US partner Acadia Pharmaceuticals (Nasdaq: ACAD) disclosing Q1 2026 DAYBUE net sales of US$101 million — a 20% increase on Q1 2025 and the highest year-on-year growth rate recorded since Q3 2024. The result prompted NEU shares to rise 4.38% to $12.86 during morning trade, as investors responded positively to evidence of accelerating DAYBUE adoption and the early-stage commercial promise of the newly launched DAYBUE STIX formulation.

For Neuren, DAYBUE's commercial performance is directly linked to its royalty income stream, which constitutes the company's primary source of Revenue. Under the terms of its exclusive worldwide licence to Acadia for the development and commercialisation of trofinetide, Neuren earns royalties on a tiered basis: 10% of DAYBUE net sales up to US$250 million and 12% of sales between US$250 million and US$500 million. With FY26 sales guidance at US$460–490 million, a meaningful portion of Neuren's royalties for the full year will be earned at the higher 12% rate.

 

Q1 2026 Royalty Performance

Neuren earned Q1 2026 royalty income of US$10.4 million, a 23% increase on the US$8.5 million earned in Q1 2025. The royalty growth rate slightly exceeds the underlying sales growth rate of 20%, which reflects the progressive movement of sales into higher royalty rate tiers as cumulative quarterly volumes increase toward the US$250 million threshold. This tiered royalty structure means that, all else equal, Neuren's royalty income should grow at a faster rate than DAYBUE net sales as the product scales toward and beyond the US$250 million tier boundary.

Full-year 2026 royalty guidance remains unchanged at between US$50 million and US$54 million, which on an AUD/USD Exchange Rate assumption of 0.70–0.72 translates to approximately A$70–77 million. These estimates are described as conservative, as they are based on North American royalty rates only, without incorporating potential royalty contributions from other markets where DAYBUE may be approved and commercialised in the future.

 

DAYBUE STIX: A New Growth Vector

One of the more strategically significant developments in the Q1 2026 update is the limited commercial launch of DAYBUE STIX — a new powder formulation of trofinetide that received FDA approval and was introduced to the US market in Q1 2026 through a focused launch at Rett syndrome Centers of Excellence (COEs) before becoming broadly available in early April. STIX represents a meaningful product lifecycle management development for DAYBUE, offering an alternative administration format that may improve convenience and adherence relative to the existing oral solution.

In Q1 2026, more than 250 STIX prescriptions were written, with approximately 30% of those prescriptions for treatment-naïve patients or patients who had previously discontinued treatment. This latter category is particularly valuable from a commercial perspective, as STIX appears to be re-engaging patients who had previously found the oral solution difficult to tolerate or administer. Caregiver satisfaction with STIX exceeded 80% and healthcare professional endorsement has been strong — metrics that bode well for broader uptake as the product transitions from a COE-focused limited launch to widespread availability.

Neuren CEO Jon Pilcher expressed particular enthusiasm for the STIX launch, noting that he sees significant upside potential remaining in the US market, with current penetration rates of approximately 60% in COEs and only 28% in the broader community. These figures suggest that a large proportion of potentially eligible Rett syndrome patients are not yet receiving DAYBUE treatment — a penetration gap that represents a meaningful commercial opportunity if STIX or other initiatives succeed in broadening access and overcoming treatment barriers.

 

Expert Consensus and International Developments

Beyond the headline sales and royalty numbers, the Q1 2026 update contained several developments relevant to DAYBUE's long-term market position. A Delphi expert consensus panel recently recommended DAYBUE as part of the standard of care for eligible patients with Rett syndrome, a designation that carries clinical and formulary significance. Standard of care endorsement by an expert consensus body can influence prescribing behaviour, payer coverage decisions, and clinical guideline development — all of which can support sustained long-term Volume growth.

Internationally, Neuren provided updates on two significant regulatory and development programs. In Japan, enrolment in the ongoing trofinetide clinical trial has accelerated, with topline results now expected in the September to November 2026 timeframe — an earlier window than the previous Q4 2026 to Q1 2027 guidance. Japan represents a potentially significant market opportunity given its large healthcare system and relatively underpenetrated rare disease treatment landscape. In Europe, the reexamination process for trofinetide is expected to conclude in June 2026, which could open the pathway to European approval and commercial launch under Acadia's commercialisation rights.

 

Pipeline Beyond DAYBUE

Neuren's growth narrative is not limited to DAYBUE royalties. The company is also developing NNZ-2591, its second drug candidate, which is in clinical development as an oral solution for multiple neurodevelopmental disorders. Positive Phase 2 results have been achieved in Phelan-McDermid syndrome, Pitt Hopkins syndrome, and Angelman syndrome — each of which has received Orphan Drug designation in the US and EU, as well as Fast Track and Rare Pediatric Disease designations from the FDA. Neuren is currently conducting a Phase 3 trial evaluating NNZ-2591 in children with Phelan-McDermid syndrome, with a 52-week open-label extension study running concurrently.

NNZ-2591 is also being developed for hypoxic ischemic encephalopathy (HIE), a serious condition caused by brain injury around the time of birth. The breadth of NNZ-2591's target indications, combined with the regulatory designations already secured, positions it as a potentially significant second revenue source for Neuren beyond its current DAYBUE royalty stream. The Phase 3 Phelan-McDermid program represents the most advanced of these development efforts and will be a key catalyst for the stock over the coming years.

 

Conclusion

Neuren Pharmaceuticals' Q1 2026 update presents a compelling picture of a royalty-generating biotech with an accelerating core product, an exciting new formulation gaining traction, and a pipeline that provides meaningful optionality beyond the current DAYBUE revenue stream. The 20% increase in DAYBUE net sales to US$101 million and the 23% growth in royalty income to US$10.4 million, combined with the intact full-year guidance and early STIX success, make for a substantive and positive quarterly update. The 4.38% share price increase on 7 May 2026 reflects growing market recognition of the quality and sustainability of Neuren's royalty Business, supported by the emerging international opportunities in Japan and Europe and the long-term potential of the NNZ-2591 pipeline.